385 related articles for article (PubMed ID: 26307094)
1. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation.
van Scherpenzeel M; Steenbergen G; Morava E; Wevers RA; Lefeber DJ
Transl Res; 2015 Dec; 166(6):639-649.e1. PubMed ID: 26307094
[TBL] [Abstract][Full Text] [Related]
2. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II.
Guillard M; Morava E; van Delft FL; Hague R; Körner C; Adamowicz M; Wevers RA; Lefeber DJ
Clin Chem; 2011 Apr; 57(4):593-602. PubMed ID: 21273509
[TBL] [Abstract][Full Text] [Related]
3. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG).
Casetta B; Malvagia S; Funghini S; Martinelli D; Dionisi-Vici C; Barone R; Fiumara A; Donati MA; Guerrini R; la Marca G
Clin Chem Lab Med; 2020 Aug; 59(1):165-171. PubMed ID: 32776892
[TBL] [Abstract][Full Text] [Related]
4. A new method for the rapid diagnosis of protein N-linked congenital disorders of glycosylation.
Heywood WE; Mills P; Grunewald S; Worthington V; Jaeken J; Carreno G; Lemonde H; Clayton PT; Mills K
J Proteome Res; 2013 Jul; 12(7):3471-9. PubMed ID: 23742123
[TBL] [Abstract][Full Text] [Related]
5. Laboratory diagnosis of congenital disorders of glycosylation type I by analysis of transferrin glycoforms.
Babovic-Vuksanovic D; O'Brien JF
Mol Diagn Ther; 2007; 11(5):303-11. PubMed ID: 17963418
[TBL] [Abstract][Full Text] [Related]
6. Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency.
Abu Bakar N; Voermans NC; Marquardt T; Thiel C; Janssen MCH; Hansikova H; Crushell E; Sykut-Cegielska J; Bowling F; MØrkrid L; Vissing J; Morava E; van Scherpenzeel M; Lefeber DJ
Transl Res; 2018 Sep; 199():62-76. PubMed ID: 30048639
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation.
Wada Y
Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821
[TBL] [Abstract][Full Text] [Related]
8. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.
Sturiale L; Barone R; Garozzo D
J Inherit Metab Dis; 2011 Aug; 34(4):891-9. PubMed ID: 21384227
[TBL] [Abstract][Full Text] [Related]
9. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation.
Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M
Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051
[TBL] [Abstract][Full Text] [Related]
10. Screening for abnormal glycosylation in a cohort of adult liver disease patients.
Jansen JC; van Hoek B; Metselaar HJ; van den Berg AP; Zijlstra F; Huijben K; van Scherpenzeel M; Drenth JPH; Lefeber DJ
J Inherit Metab Dis; 2020 Nov; 43(6):1310-1320. PubMed ID: 32557671
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II.
Al Teneiji A; Bruun TU; Sidky S; Cordeiro D; Cohn RD; Mendoza-Londono R; Moharir M; Raiman J; Siriwardena K; Kyriakopoulou L; Mercimek-Mahmutoglu S
Mol Genet Metab; 2017 Mar; 120(3):235-242. PubMed ID: 28122681
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry for congenital disorders of glycosylation, CDG.
Wada Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 838(1):3-8. PubMed ID: 16517226
[TBL] [Abstract][Full Text] [Related]
13. Serum transferrin carrying the xeno-tetrasaccharide NeuAc-Gal-GlcNAc2 is a biomarker of ALG1-CDG.
Bengtson P; Ng BG; Jaeken J; Matthijs G; Freeze HH; Eklund EA
J Inherit Metab Dis; 2016 Jan; 39(1):107-14. PubMed ID: 26335155
[TBL] [Abstract][Full Text] [Related]
14. Transferrin variants: pitfalls in the diagnostics of Congenital disorders of glycosylation.
Zühlsdorf A; Park JH; Wada Y; Rust S; Reunert J; DuChesne I; Grüneberg M; Marquardt T
Clin Biochem; 2015 Jan; 48(1-2):11-3. PubMed ID: 25305627
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of congenital disorders of glycosylation type-I using protein chip technology.
Mills K; Mills P; Jackson M; Worthington V; Beesley C; Mann A; Clayton P; Grunewald S; Keir G; Young L; Langridge J; Mian N; Winchester B
Proteomics; 2006 Apr; 6(7):2295-304. PubMed ID: 16552784
[TBL] [Abstract][Full Text] [Related]
16. Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
Abu Bakar N; Ashikov A; Brum JM; Smeets R; Kersten M; Huijben K; Keng WT; Speck-Martins CE; de Carvalho DR; de Rizzo IMPO; de Mello WD; Heiner-Fokkema R; Gorman K; Grunewald S; Michelakakis H; Moraitou M; Martinelli D; van Scherpenzeel M; Janssen M; de Boer L; van den Heuvel LP; Thiel C; Lefeber DJ
J Inherit Metab Dis; 2022 Jul; 45(4):769-781. PubMed ID: 35279850
[TBL] [Abstract][Full Text] [Related]
17.
Kodríková R; Pakanová Z; Krchňák M; Šedivá M; Šesták S; Květoň F; Beke G; Šalingová A; Skalická K; Brennerová K; Jančová E; Baráth P; Mucha J; Nemčovič M
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831116
[TBL] [Abstract][Full Text] [Related]
18. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry to Detect Diagnostic Glycopeptide Markers of Congenital Disorders of Glycosylation.
Wada Y
Mass Spectrom (Tokyo); 2020; 9(1):A0084. PubMed ID: 32547898
[TBL] [Abstract][Full Text] [Related]
19. Use of Endoglycosidase H as a diagnostic tool for MAN1B1-CDG patients.
Duvet S; Mouajjah D; Péanne R; Matthijs G; Raymond K; Jaeken J; Morava E; Foulquier F
Electrophoresis; 2018 Dec; 39(24):3133-3141. PubMed ID: 29947113
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
